Company / Depreciation & Amortization
Mirum Pharmaceuticals, Inc. Depreciation & Amortization History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$24.2M
FY2025
5-year range
$305.0K / $24.2M
FY2021-FY2025
Trend
+2.6%
vs FY2024
Sector context
#42 of 163
Health Care
What the data says
At $24M, Mirum Pharmaceuticals, Inc.'s depreciation & amortization ranks #122 of 163 in the Health Care sector. Depreciation & Amortization has increased for 4 consecutive years, from $305,000 in FY2021 to $24M in FY2025.
Based on SEC 10-K filings.
$24M in FY2025 with a 5-year CAGR of +139.9%.
Increased from $11M to $24M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +244.1%
- 5-Year CAGR
- +139.9%
- 10-Year CAGR
- -
Sector benchmark
#122 of 163 in Health CareTop 74% of 163This company $24.2M Sector average $219.4M
▼
-89.0% below sector average
Key checks
Key Insights
- Mirum Pharmaceuticals, Inc.'s depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +139.9%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 2.6% year-over-year.
- Ranks #42 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.2M | +2.6% |
| FY2024 | $23.6M | +118.2% |
| FY2023 | $10.8M | +1720.0% |
| FY2022 | $595.0K | +95.1% |
| FY2021 | $305.0K | +0.0% |
| FY2020 | $305.0K | +119.4% |
| FY2019 | $139.0K | - |
| FY2018 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026